^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Adenocarcinoma

    Related cancers:
    1d
    Collision tumor of endometrial hepatoid adenocarcinoma and endometrial stromal sarcoma: a rare case and literature review. (PubMed, Front Oncol)
    In this context, the CAP regimen-comprising cyclophosphamide, adriamycin, and cisplatin-has demonstrated superior overall efficacy. Moreover, these tumors seem to be relatively resistant to radiation therapy.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide
    11d
    ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (clinicaltrials.gov)
    P1, N=58, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • Modeyso (dordaviprone)
    11d
    ATX-559-001: First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers (clinicaltrials.gov)
    P1, N=17, Terminated, Accent Therapeutics | N=100 --> 17 | Trial completion date: Feb 2027 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; The study was terminated by sponsor based on the adverse event profile.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • HER-2 negative
    13d
    Human epidermal growth factor receptor 2 expression in gynecologic serous carcinomas and preliminary analysis of its characteristics in patients post-neoadjuvant chemotherapy. (PubMed, Front Oncol)
    Moreover, our findings suggest that HER2 status could be a relevant prognostic marker in these malignancies. Traditional anti-HER2 targeted therapies are indicated for HER2-positive patients, while a broader population of patients with HER2-low expression may benefit from novel anti-HER2 antibody-drug conjugates.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 underexpression • HER-2 positive + HER-2 overexpression
    20d
    The Umbilical Clue: Recognizing Sister Mary Joseph's Nodule. (PubMed, Eur J Case Rep Intern Med)
    Clinical significance: Sister Mary Joseph's nodule (SMJN) represents a rare but important clinical sign of metastatic intra-abdominal or pelvic malignancy, often indicating advanced disease.Clinical awareness: Heightened awareness of umbilical lesions among clinicians is essential, particularly in elderly patients presenting with nonspecific systemic symptoms such as weight loss, asthenia, or abdominal pain.Early diagnosis of SMJN is essential, as it frequently signifies advanced metastatic disease. Prompt recognition allows timely initiation of appropriate therapy or palliative care to optimize patient outcomes.
    Journal
    |
    CDX2 (Caudal Type Homeobox 2) • PAX8 (Paired box 8)
    28d
    Risk of second non-breast primary cancer in Chinese breast cancer patients with germline BRCA1/2 pathogenic variants. (PubMed, Breast Cancer Res Treat)
    BRCA1/2 carriers exhibit a 2- to 3-fold higher risk of second primary cancer than non-carriers. Ovarian cancer represents the majority of second primary cancers in BRCA1 carriers, while BRCA2 carriers have a wider spectrum of second primary cancers.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    1m
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    2ms
    Galectin-3 in endometrial small extracellular vesicles promotes cytotrophoblast cell fusion during the implantation phase. (PubMed, Cell Commun Signal)
    Our findings demonstrate that endometrial sEVs enriched in galectin-3 during the implantation phase promote CT differentiation into ST, underscoring a novel role for sEV-mediated protein delivery in regulating early placental development and suggesting potential diagnostic and therapeutic applications in reproductive medicine.
    Journal
    |
    LGALS3 (Galectin 3)
    2ms
    Spectrum of Histopathological Changes in Abnormal Uterine Bleeding with Estrogen and Progesterone Receptor Expression in Endometrial Hyperplasia and Carcinoma. (PubMed, J Midlife Health)
    Serous papillary-type carcinoma also showed negative expression. Endometrial carcinoma showed reduced hormonal expression compared to endometrial hyperplasia.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    2ms
    A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University of Florida | Initiation date: Nov 2025 --> Mar 2026
    Trial initiation date
    2ms
    Oxidative Stress Influences Exosome Biogenesis by Inducing Cellular Senescence in Uterine Adenocarcinoma Ishikawa Cells. (PubMed, Iran J Med Sci)
    Cells were treated with 20 μM hydrogen peroxide (H2O2) for 4 days, and physicochemical properties of Exos were analyzed using dynamic light scattering (DLS), scanning electron microscope (SEM), and western blotting. The expression of genes such as ALIX, CD63, TSG101, Rab27a, and Rab27b, along with aging factor senescence-associated
    Journal
    |
    RAB27A (RAB27A, Member RAS Oncogene Family) • TSG101 (Tumor Susceptibility 101)